[The action of a new calcium antagonist 5,6-dimethoxy-2-(3 [(alpha-(3,4-dimethoxy)-phenylethyl)methylamino] propyl)-phthalimidine hydrochloride (AQ-A 39cl) on hemodynamics and ischemia parameters in exercise ECG of patients with coronary heart disease].
Six patients with angiographically documented coronary artery disease underwent multiple exercise tests before and after randomized double-blind crossover treatment with 200 mg 5,6-dimethoxy-2-(3[(alpha-(3,4-dimethoxy)phenylethyl)methylamino] propyl)-phthalimidine-hydrochloride (AQ-A 39 cl, in the following briefly called AQ-A 39) intravenously. Changes in ST-segment depression, angina pectoris, heart rate and blood pressure were evaluated. After AQ-A 39, the sum of ST-segment depression was significantly reduced compared with control and placebo by 48% (2p less than 0.025) and 42% (2p less than 0.05) respectively, maximal ST-segment depression by 45% (2p less than 0.025) and 35% (2p less than 0.05), respectively; the duration of angina pectoris was reduced by 50% and 33%, respectively. AQ-A 39 reduced heart rate at rest and during exercise; blood pressure, however, was not significantly altered. In conclusion, AQ-A 39 is an antianginal drug, which acts most probably by cardiac mechanisms and not by reduction of afterload. Thus, further studies about AQ-A 39 or its derivatives seem to be useful.